Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 5

1.

Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.

Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu W, Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST.

Cancer Discov. 2012 Jul;2(7):591-7. doi: 10.1158/2159-8290.CD-12-0028. Epub 2012 Jun 15.

2.

Treating inflammation with the Janus kinase inhibitor CP-690,550.

Vijayakrishnan L, Venkataramanan R, Gulati P.

Trends Pharmacol Sci. 2011 Jan;32(1):25-34. doi: 10.1016/j.tips.2010.10.004. Epub 2010 Dec 7. Review.

PMID:
21144599
3.

Mining for JAK-STAT mutations in cancer.

Constantinescu SN, Girardot M, Pecquet C.

Trends Biochem Sci. 2008 Mar;33(3):122-31. doi: 10.1016/j.tibs.2007.12.002. Review.

PMID:
18291658
4.

JAK3: a two-faced player in hematological disorders.

Cornejo MG, Boggon TJ, Mercher T.

Int J Biochem Cell Biol. 2009 Dec;41(12):2376-9. doi: 10.1016/j.biocel.2009.09.004. Epub 2009 Sep 9. Review.

5.

Tofacitinib.

[No authors listed]

Drugs R D. 2010;10(4):271-84. doi: 10.2165/11588080-000000000-00000. Review. Erratum in: Drugs R D. 2012 Mar 1;12(1):41-3. Dosage error in article text.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk